Navigation Links
Exosome Diagnostics Presents Data at American Urology Association Demonstrating Potential Utility of Urine Exosomes to Non-invasively Detect and Manage Prostate Cancer
Date:5/23/2012

NEW YORK, May 23, 2012 /PRNewswire/ -- Exosome Diagnostics, a leading developer of biofluid-based molecular diagnostic tests for use in personalized and non-invasive cancer diagnostics, today presented two clinical studies demonstrating the potential utility of non-invasive sampling of patients' urine to detect and manage prostate cancer. 

In the first study, the presence of a prostate cancer-specific biomarker in exosomes collected from random patients' urine samples demonstrated a strong correlation to the presence of that marker in prostate tissue removed via radical prostatectomy (RP).  The study also correlated the expression level of the marker in urine with the likelihood of a positive cancer biopsy. 

In a second study, urinary exosomes demonstrated elevated levels of survivin messenger RNA (mRNA) from patients with castration-resistant prostate cancer (CRPC) following primary therapy.  Survivin expression has been implicated in hormone-independent prostate cancer growth.

"These studies, led by our director of research, Dr. Leileata Russo and conducted by our clinical collaborators, are part of our prostate cancer in vitro molecular diagnostics program," said James McCullough, chief executive officer of Exosome Diagnostics. "The urinary exosome provides us with a stable source of RNA that we can interrogate using qPCR to non-invasively analyze different stages of prostate cancer."  

Motamedinia et al. (abst. # 2108) obtained random samples of urine from men and measured the concordance of prostate cancer with detection of the biomarker, TMPRSS2:ERG (T:E).  The investigators found that TMPRSS2:ERG expression occurred in 17 of 21 post-RP tissue samples.  They also found that T:E expression in urinary exosomes from non-digital rectal exam (DRE) patients was nine-fold higher in the prostate biopsy positive patients versus biopsy negative patients. The study also demonstrated a high level of concordance between exosome-biomarker signature and the marker's presence in cancerous prostate tissue. 

"The diagnosis and management of prostate cancer and patients with elevated PSA remains challenging for both patients and their physicians," said James McKiernan, M.D., the John and Irene Given professor of Urology, director of Urologic Oncology, Columbia University Medical Center and co-author of the study.  "Patients with high PSA results must decide whether to undergo a biopsy procedure, which in itself may not be definitive as further suggested from the results of the study.  A reliable, non-invasive diagnostic test that can determine the presence and nature of a prostate malignancy as well as its response to treatment would be of great value.  The biofluid-based technology highlighted in this study is a very promising approach to reaching this goal."

Lin et al. (abst. # 2232), investigated the relationship of survivin expression measured in exosomes and the disease status of patients diagnosed with CRPC. The presence of survivin, an inhibitor of apoptosis, has been implicated as a factor in hormone-independent tumor growth.  Survivin expression was higher in patients with measurable disease than in patients without disease and this was correlated with castration resistance. 

"Monitoring patient response to treatment is largely limited to PSA testing and new tools are needed," said Daniel Petrylak, M.D., associate professor of medicine, Columbia University Medical Center and co-author of the study.  "The non-invasive biofluid test we employed in this study directly measures one component of the genetic profile of malignant prostate cells.  This approach should enable us to better understand a patient's response to treatment and, if an alternative therapy is required, an analysis of exosome RNA and DNA content could better direct a treatment decisions."

Exosomes are one of many different sub-populations of microvesicles that can be isolated from biofluids such as blood, urine and cerebrospinal fluid (CSF).  Exosomes are shed by cells under both normal and pathological conditions.  These vesicles contain high quality RNA and DNA that can be extracted and purified for analysis. 

About Exosome Diagnostics
Exosome Diagnostics is a leading developer of biofluid-based molecular diagnostic tests for use in personalized medicine. Exosomes are shed into all biofluids, including blood, urine and CSF, forming a stable source of intact, disease-specific nucleic acids. The Company's proprietary exosome technology makes use of this natural stability to achieve high sensitivity for rare gene transcripts and the expression of genes responsible for cancers and other diseases. The Company is commercializing in vitro diagnostic tests for use in companion diagnostic applications and real-time monitoring of disease. Exosome Diagnostics' development program is focused on blood, urine and cerebrospinal fluid with programs in collaboration with the Prostate Cancer Foundation in prostate cancer and Accelerate Brain Cancer Cures in brain cancer.  The Company maintains facilities in New York, St. Paul, MN and Munich, Germany. For more information, please visit www.exosomedx.com.

 


'/>"/>
SOURCE Exosome Diagnostics
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Accelerate Brain Cancer Cure and Exosome Diagnostics Collaborate to Advance Clinical Studies of Exosome Biofluid Molecular Diagnostics Technology in Brain Cancer
2. EUR 1.0 Million Grant Awarded to Exosome Diagnostics and Ludwig Maximilian University from German Federal Ministry for Education and Research to Develop Biofluid-Derived Exosome Diagnostics
3. Exosome Diagnostics Announces Additions to Management and Scientific Advisory Board as Company Expands Clinical Validation Studies in Oncology
4. Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board
5. Exosome Diagnostics Appoints Former Roche Executive Greg Zdechlik as Chief Operating Officer
6. Exosome Diagnostics and DxS Diagnostic Innovations Collaborate to Develop Blood-Based Tests for Key Cancer Mutations
7. Exosome Diagnostics Appoints Johan Skog, Ph.D., as Director of Genetics Research
8. Exosome Diagnostics Announces Additions to Management Team
9. Ariosa Diagnostics Announces Publication of Study on Influential Factors Affecting Fetal DNA Concentration in Blood of Pregnant Women
10. Ariosa Diagnostics Announces Nationwide Launch of the Harmony™ Prenatal Test Through LabCorp
11. QIAGEN Joins Grand Challenges in Global Health Initiative to Bring Advanced Point-of-Care Diagnostics to Worlds Poorest Countries
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... York, NY (PRWEB) , ... April 28, 2016 ... ... QuickSTAT has made significant investments in recruiting top industry experts, and expanding its ... Platform, which provides industry-leading tools for clients to manage their clinical trial projects. ...
(Date:4/27/2016)... ... 2016 , ... Shimadzu Scientific Instruments (SSI) will be showcasing ... Conference and Expo. Shimadzu’s high-performance instruments enable laboratories to test cannabis products for ... stop by booth 1021 to learn how Shimadzu’s instruments can help improve QA/QC ...
(Date:4/27/2016)... Columbia , April 27, 2016 ... "NanoStruck") (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... Anschluss an ihre Pressemitteilung vom 13. August 2015 ... hat, ihre Finanzen um zusätzliche 200.000.000 Einheiten auf ... Kanadische Dollar zu bringen. Davon wurden 157.900.000 Einheiten ...
(Date:4/27/2016)... VIRGINIA (PRWEB) , ... April 27, 2016 , ... ... today that Jon Clark has joined the company as an Expert Consultant. ... responsible for industry collaborations and managing the development of small molecule monographs based ...
Breaking Biology Technology:
(Date:3/9/2016)... This BCC Research report provides an overview ... Sequencing (RNA Seq) market for the years 2015, 2016 ... reagents, data analysis, and services. Use this ... market such as RNA-Sequencing tools and reagents, RNA-Sequencing data ... each segment and forecast their market growth, future trends ...
(Date:3/8/2016)... 2016   Valencell , the leading innovator ... has secured $11M in Series D financing. The ... venture fund being launched by UAE-based financial services ... investors TDF Ventures and WSJ Joshua Fund. Valencell ... triple-digit growth and accelerate its pioneering innovation in ...
(Date:3/3/2016)... and DE SOTO, Kansas ... U.S.-based Stroke Detection Plus® to offer Oncimmune,s Early ... assessment and early detection of lung cancer ... employers, unions and individuals. --> Early CDT®-Lung ... and individuals. --> Oncimmune, a leader in ...
Breaking Biology News(10 mins):